OBJECTIVE： To study the effects of mifepristone on related indexes of patients with myomectomy. METHODS： The information of 100 patients with uterine fibroids were analyzed retrospectively， and they were divided into observation group and control group according to therapy method， with 50 cases in each group. Control group only received myomectomy. Observation group was given Mifepristone tablets 10 mg orally， qd， for consecutive 3 months， and then received myomectomy within 2 d after drug withdrawal； they were given Mifepristone tablets 10 mg/d orally after surgery， for consecutive 3 months. The 2 groups were followed up for 6 months. The maximual volume of uterine fibroids and the volume of uterus were compared between 2 groups as well as related operation indicator， levels of serun reproductive hormones，sex hormones of uterine myoma tissure and related growth factors of uterus myomas. The recurrence and occurrence of ADR was recorded during treatment. RESULTS： Before surgery， the maximual volume of uterine fibroids and the volume of uterus in observation group were significantly lower than control group， with statistical significance（P＜0.05）. The operation time， vaginal bleeding time and hospital stay of observation group were significantly shorter than those of control group， the intraoperative blood loss and the recurrence rate were significantly lower than those of control group， with statistical significance （P＜0.05）. Six months after surgery， ER， PR， EGFR， TGF-β1R and IGF-1R of uterus myomas in observation group were significantly lower than those of control group， with statistical significance （P＜0.05）. There was no statistical significance in the levels of FSH、E2 and P level of uterus myomas between 2 groups in first diagnosis and 6 months after surgery（P＞0.05）. No obvious ADR was found in 2 groups during treatment. CONCLUSIONS： Mifepristone helps to reduce operative time， intraoperative blood loss，vaginal bleeding time and hospital stay of patients with myomectomy， and may be related to the regulation of ER and PR levels and related growth factor receptors.